Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib and Quercetin in Diabetic Chronic Kidney Disease
NCT02848131Phase 2Enrolling by invitation
- Sponsor
- Mayo Clinic
- Start
- Jul 2016
- Primary completion
- Apr 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib, quercetin in chronic kidney disease (CKD), sponsored by Mayo Clinic. Started Jul 2016; status: enrolling by invitation.
02
Drugs
dasatinibquercetin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT02848131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02848131.